TH103

TH103 is a fully humanized, recombinant fusion protein engineered as a next-generation anti-VEGF (vascular endothelial growth factor) therapy for retinal diseases. Developed by Dr. Napoleone Ferrara, the scientist behind Avastin and Lucentis, TH103 acts as a soluble decoy receptor that binds VEGF with high affinity, thereby inhibiting its activity and suppressing abnormal blood vessel growth in the retina. The drug is designed for intravitreal administration and has been optimized for longer ocular residence time and enhanced potency compared to existing anti-VEGF agents. Its primary indication is neovascular (wet) age-related macular degeneration (nAMD), with ongoing Phase 1 clinical trials evaluating safety, pharmacokinetics, and preliminary efficacy. Preclinical data suggest superior durability and efficacy over current standard-of-care therapies like aflibercept[1][3][4][6][7][9][10].